LubioScience GmbH, Switzerland’s leading life science distributor, has partnered with Zymo Research to bring specialized Next-Generation Sequencing (NGS) services for epigenetics and microbiomics to the Swiss market. This collaboration enables Swiss biotech companies to obtain reliable NGS data with faster turnaround times and highly competitive pricing.

 Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical study AMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical enzymes on the lining of the intestinal brush border

RespiriNTM Programme allows BioVersys’ NTM project to access up to €2 million of non-dilutive funding BioVersys taps into key expertise of the established RespiriNTM consortium members and will lead development of its candidates through preclinical and clinical studies BioVersys’ NTM candidates are derived from the company’s proprietary Ansamycin Chemistry platform and are being developed

Topadur Pharma AG, a Swiss clinical-stage biotechnology company, today announces the appointments of PD Dr. Matthias Schäfer as Chief Innovation Officer (CIO) and Prof. Dr. Jay Siegel as Chief Research Officer (CRO).

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V), the world’s most clinically advanced tetravalent bioconjugate shigello